 Carbidopa
"Carbidopa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitor of DOPA DECARBOXYLASE, preventing conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no antiparkinson actions by itself.
| Descriptor ID |
D002230
|
| MeSH Number(s) |
D02.092.311.200.538.200 D02.442.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Carbidopa".
Below are MeSH descriptors whose meaning is more specific than "Carbidopa".
This graph shows the total number of publications written about "Carbidopa" by people in this website by year, and whether "Carbidopa" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 0 | 2 | 2 | | 1982 | 1 | 2 | 3 | | 1983 | 1 | 1 | 2 | | 1984 | 1 | 1 | 2 | | 1986 | 0 | 1 | 1 | | 1987 | 2 | 1 | 3 | | 1988 | 1 | 1 | 2 | | 1989 | 1 | 0 | 1 | | 1991 | 0 | 1 | 1 | | 1993 | 1 | 1 | 2 | | 1996 | 2 | 0 | 2 | | 1997 | 1 | 0 | 1 | | 1998 | 0 | 2 | 2 | | 1999 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 | | 2009 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Carbidopa" by people in Profiles.
-
Hauser RA, LeWitt PA, Comella CL. On demand therapy for Parkinson's disease patients: Opportunities and choices. Postgrad Med. 2021 Sep; 133(7):721-727.
-
Hinson VK, Goetz CG, Leurgans S, Fan W, Nguyen T, Hsu A. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clin Neuropharmacol. 2009 Jul-Aug; 32(4):189-92.
-
Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, Fahn S. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology. 2008 Aug 12; 71(7):481-5.
-
Hall DA, Berry-Kravis E, Hagerman RJ, Hagerman PJ, Rice CD, Leehey MA. Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome. Mov Disord. 2006 Oct; 21(10):1741-4.
-
Kompoliti K, Adler CH, Raman R, Pincus JH, Leibowitz MT, Ferry JJ, Blasucci L, Caviness JN, Leurgans S, Chase WM, Yones LC, Tan E, Carvey P, Goetz CG. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 May 14; 58(9):1418-22.
-
Barboi AC, Goetz CG. Parkinson's disease. Clin Neuropharmacol. 1999 Jul-Aug; 22(4):184-91.
-
Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology. 1998 Sep; 51(3):811-4.
-
Goetz CG. Highlights of the North American and European experiences. Neurology. 1998 May; 50(5 Suppl 5):S15-6.
-
Pappert EJ, Lipton JW, Goetz CG, Ling ZD, Stebbins GT, Carvey PM. The stability of carbidopa in solution. Mov Disord. 1997 Jul; 12(4):608-10.
-
Pappert EJ, Goetz CG, Niederman F, Ling ZD, Stebbins GT, Carvey PM. Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology. 1996 Dec; 47(6):1493-5.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|